Why the study?
Does olmesartan medoxomil and hydrochlorothiazide combination therapy improve blood pressure reduction in patients with hypertension compared to monotherapy?
Does olmesartan medoxomil and hydrochlorothiazide combination therapy improve blood pressure reduction in patients with hypertension compared to monotherapy?
The combination of olmesartan medoxomil and hydrochlorothiazide provides greater blood pressure reduction and goal attainment than monotherapy without compromising tolerability.
Answers are grounded in this paper and cite their sources.
May support olmesartan-HCTZ combo for BP goals; hypothesis-generating and leaves open prospective RCTs.
In at least 50% of patients with hypertension, particularly those with stage 2 hypertension, combination drug therapy is required to achieve the currently recommended blood pressure (BP) goals. It is likely that future hypertension guidelines will recommend lowering BP beyond the currently recommended systolic/diastolic BP goals of lower than 140/90 mmHg for all patients with hypertension and lower than 130/80 mmHg for patients with diabetes or chronic kidney disease. In a series of clinical trials, the combination of olmesartan medoxomil, a well-established angiotensin receptor blocker, and hydrochlorothiazide, a thiazide diuretic, has produced greater reductions in systolic BP and diastolic BP and greater proportions of patients achieving BP goals than monotherapy with either component. Additionally, the increased efficacy resulting from the combination with hydrochlorothiazide does not appear to significantly affect the tolerability profile of olmesartan medoxomil. This article provides a comprehensive evaluation of the chemistry, clinical efficacy, safety and tolerability of this combination and discusses its role in the management of hypertension.
No takes yet. Share an insight, caveat, or question.
Henry Punzi (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: